principle isoform in humans and produced by endothelin cells, vascular smooth muscle cells, epithelial cells, neutrophils, macrophages and fibroblasts [7] .
Human endothelin derives from a 212 aa precursor, preproendothelin-1, which is intracellularly cleaved by endothelin converting enzyme-1 and 2 (ECE-1 and ECE-2) [8] . Removal of single sequence generates the 195 aa proendothelin-1, which is further processed to release the intermediate 38 aa "big ET-1". ECEs hydrolyse big ET-1 to yield the active 21aa ET-1 [6] . Big ET-1 has a circulating half-life of "23min" compared with only "3.5 min" for ET-1 [9] . So, big ET-1 with its long half-life has been implicated as a more accurate indicator of the activation degree of the endothelin system [10] .
Endothelins have numerous potential roles in tumors including modulating angiogenesis, inducing mitogenesis and invasion of tumors cells and protecting cells from apoptosis [6] . In breast cancer, expression of components of the endothelin system has been associated with the transition from normal tissue to progressively invasive lesions [11] . A large number of serum tumor markers have been proposed for breast cancer, among them, carbohydrate antigen 15.3 (CA 15.3) which is the most commonly used in clinical practice. CA15.3 is well characterized assay in peripheral blood that allows the detection of circulating MUC-1 antigen. MUC-1, which is one of cell surface associated mucin, is aberrantly over expressed in many adenocarcinomas especially breast cancer [12] .
The study was designed to investigate the serum big ET-1 levels in newly diagnosed primary breast cancer patients; before surgery and after adjuvant therapy. In addition this study was also aimed at examining the correlation between big ET-1 and CA15.3, clinical and pathological criteria of breast cancer, as well as their status during the follow up period after adjuvant therapy.
Patients and methods
The present study was carried out on 40 consecutive female patients with newly diagnosed primary breast cancer at different clinical stages, admitted to the Surgical Department and followed up in the Department of Cancer Management and Research at Medical Research Institute, University of Alexandria within the period from 2010 to 2012. Fifteen healthy females were selected as a control group with matched ages.
Selected patients met the following criteria: all have primary invasive breast carcinoma with no clinical manifestation of infection and did not receive any immunomodulatory agent in the previous 3 weeks or a blood transfusion before surgery.
All patients were subjected preoperatively to the following: full medical history taking, detailed clinical examination, mammography and ultrasonography of the breast, plain X-ray of the chest, abdominal ultrasound, routine laboratory investigations, fine needle aspiration and/or core cutting needle biopsy from the breast to detect malignancy. Other radiological investigations were done during the follow up period including: CT of abdomen, chest, brain, together with isotopic bone scan for detection of metastasis if indicated. Furthermore, all patients were treated by different surgical techniques followed by proper adjuvant therapy protocols based on tumor stage and risk factors.
During the follow up period (1 year after finishing the adjuvant protocol therapy), 9 patients developed metastasis (22.5%). Therefore, breast cancer patients were re-divided into non-metastatic group (n31) and metastatic group (n9).
Blood samples
Two blood samples (5ml) were withdrawn from all breast cancer patients; the first sample was taken one day before surgery while the second sample was taken immediately after the completion of the adjuvant therapy protocol. In the follow up period, an additional blood sample was withdrawn for patients who developed metastasis before the initiation of a new adjuvant therapy protocol, while one blood sample was taken from the control group.
All blood samples were collected into sterile tubes, left to clot then centrifuged at 25c for 10 minutes. The serum supernatant was stored at -80c until used for determination of big ET-1 and CA15.3.
Assay of biochemical parameters
Big ET-1 levels were measured with an enzyme-linked immunosorbent assay, according to manufacturer instructions (Biomedica Group Gmbh, Vienna, Austria) [13] . CA15.3 levels were measured with immunoradiometric assay (DIAsource Immuno Assay S.A. Belgium) [14] .
Quality control
All individuals agreed to participate after explaining to them the objectives of the study and signed an informed consent. Moreover, the study was approved by the local Institutional Ethical Committee.
Statistical analysis
Data management and analysis were performed using the Predictive Analytics Software (PASW Statistics version 18) and represented as mean  SE.
For abnormally distributed data, Mann-Whitney test was used to analyze two independent populations and Wilcoxon signed ranks test was used to compare the different periods. Correlations between the biochemical parameters and the studied quantitative variables were assessed using Spearman coefficient.
Agreement of the different predictives with the outcome was used and expressed in sensitivity (which is defined as the proportion of people with the disease who have a positive result {a/ (a + c)}) and specificity (which is defined as a proportion of the people without the disease who have a negative result {d/ (b + d)}), where: a  true positive cases, b  false positive cases, c  false negative cases, and d  true negative cases [15] . The ROC curve analysis was used to compare the diagnostic values of big ET-1 and CA15.3 depending on the area under the ROC curve (AUC). The higher AUC corresponds to a better diagnostic test. A P value of less than 0.05 was considered statistically significant. Abbreviations: p(*)= values as compared to the control group using Mann Whitney test; p (♦)=values as compared to breast cancer patients group before surgery using Wilcoxon signed ranks test; p (¤)= values as compared to the non metastatic patients group after the adjuvant therapy using Mann Whitney test; p (**)= values as compared to metastatic group after the adjuvant therapy using Wilcoxon signed ranks test.
There was no statistically significant difference in the serum big ET-1 and CA15.3 levels of all cancer breast patients before surgery with any of the clinicopathological parameters and patient characteristics (Table 5) .
Before surgery, serum big ET-1 showed statistically significant AUC (100%, P0.001) with sensitivity (80%) and specificity (100%) at a cut-off (2.0 fmol/ml), while serum CA15.3 showed insignificant AUC (0.663, P0.065) ( Figure 1 and Table 6 ).
Furthermore, the ROC curve analysis was used to evaluate the prognostic performance of both markers before surgery to predict metastasis. Unfortunately, it revealed that both of them performed poorly in identifying patients who developed metastasis from those who did not (AUC0.588, p0.427) and (AUC0.538, p0.734) respectively ( Figure 2 and Table 7 ). Differences were considered statistically significant at P ≤ 0.05. Abbreviations: P (*)= refers to comparison between CA15.3 measured after metastasis to control group using Mann Whitney test; P (♦)= refers to comparison between CA15.3 measured after metastasis and to breast cancer patients group before surgery using Wilcoxon signed ranks test; P (¤)= refers to comparison between CA15.3 measured after metastasis and to the non metastatic patients group after the adjuvant therapy using Mann Whitney test; P(**)= refers to comparison between CA15.3 measured after metastasis and after the adjuvant therapy using Wilcoxon signed ranks test.
Table 5
Correlation between the studied biochemical parameters and clinicopathological parameters and characteristics of breast cancer patients groups before surgery (n=40).
Clinicopathological parameters and patient characteristics
Biochemical parameters Differences were considered statistically significant at P ≤ 0.05. Abbreviations: r= Spearman coefficient 
Discussions
Current management of breast cancer focused on early diagnosis and individual care. This was mainly due to improvements in imaging methods, the discovery of novel biomarkers, and the development of tailored therapies. The discovery of specific biomarkers of predictive, prognostic, and diagnostic value over the past few decades had significantly contributed to this task [16] .
With the objective of improving breast cancer control, the researchers investigated serum big ET-1 levels in newly diagnosed patients with breast cancer, in addition to big ET-1 correlation with CA15.3, clinical and pathological criteria of breast cancer patients, as well as the outcome of the disease.
The progression of breast cancer depended on the development of vascularization. In addition to the vascular endothelial growth factor pathway, the ET pathway played a critical role in such development [17] . The biological precursor big ET-1 had a much longer half-life than ET-1 and was mainly cleared through the kidney and liver [9, 18] . It had been demonstrated that human breast cancer cells express the ECE, which converted big ET-1 to ET-1 [19] . Therefore, big ET-1 could be considered a candidate marker for the investigation of the ET-1 secretory activity [9] .
This study revealed that serum levels of big ET-1 were significantly higher in all breast cancer patients before surgery than in the control group. This could be due to the deregulation of ECE expression or activity affecting the balance between the precursor molecule and its active form [20] or simply due to the presence of the tumor [21] . Serum levels of big ET-1 in all patients significantly decreased after finishing the adjuvant therapy protocol recording normal levels. This could be attributed to the removal of the tumor as well as the effect of the adjuvant therapy itself. These findings are consistent with other researches [21] [22] [23] [24] .
The serum level of CA15.3 showed no significant difference between breast cancer patients and control group, neither before surgery nor after the adjuvant therapy. This emphasizes the idea that CA15.3 is not suitable for the diagnosis of early or localized form of breast cancer [25, 26] .
The main utility for CA15.3 was for monitoring therapy in patients with metastatic breast cancer [27] . In this research, patients who developed metastasis during the follow up period their CA15.3 levels were significantly increased as compared to their corresponding levels; before surgery, after the adjuvant therapy and also to the control group. These findings were consistence with other researcher results who found that circulating levels of CA15.3 were higher in breast cancer patients with progression or metastatic disease [25] . In another study, CA15.3 levels were increased in only 3% of patients with localized cancer while it was increased up to 70% of patients with metastatic disease [28] .This might be due to the over expression of the MUC-1 gene which encodes CA15.3 [29] or simply related to tumor burden [12] .
No third sample was taken at the end of follow up period for the non-metastatic group of patients for measuring serum levels of big ET-1 and CA15.3. Therefore, further research is needed to explore the change of these biochemical markers among that group of patients after therapy.
The results of this study did not show any significant correlation between the two markers and age, tumor size, pathological grade, lymph node status, hormone receptor status, and menopausal status. This observation was in accordance with other studies [16, 21] that stated that there was no correlation between circulating big ET-1 and tumor size, thus the increase in big ET-1 was due to a difference in production and secretion rate of tumors. Besides, the lack of a correlation between CA15.3 and the clinicopathological characteristics was due to cytokines which depend on the neoplasm activity and not on the stage of the disease or the histological type of the tumor [25, [30] [31] [32] .
The use of AUC confirmed the validity of ET-1 in the diagnosis of breast cancer. The sensitivity and specificity of big ET-1 at the estimated cut-off value of 2 fmol /ml was 80 and 100% respectively. On the contrary CA15.3 failed to discriminate between the breast cancer and the control groups (AUC66.3%, p.05). This finding was in accordance with previous studies which emphasized that CA15.3 lack in sensitivity for the early diagnosis of breast cancer [32, 33] . In the study population both biochemical markers were not able to predict early breast cancer metastasis. However, this might be due to small sample size (9 cases in the metastatic group).
Conclusions
This study found that the testing for serum big ET-1 is more useful than CA15.3 for the diagnosis of breast cancer and future trials will be necessary to establish the importance of big ET-1 as a prognostic marker and to formulate a time-line for its measurement in patients with high risk for developing metastasis.
